The Center for Blood Disorders provides comprehensive care services for the treatment of bleeding and clotting disorders and sickle cell disease.

Our physicians, nurses and social workers are available to provide personalized care for those with:

  • sickle cell disease
  • hemophilia
  • von Willebrand disease
  • thrombophilia

We are affiliated with the Medical College of Georgia at Augusta University.

Exterior view of the Walter L. Shepeard Building

Contact Us

Center for Blood Disorders

Health Sciences Campus

Walter L. Shepeard Building



Information for Patients

Learn More About Our Services

Sickle Cell Center

Hemophilia Treatment Center

Thrombophilia Care Program

Hemoglobinopathy Lab

Our Mission

Our goal is to improve quality of life for people with blood disorders through comprehensive care, addressing the physical, emotional, spiritual, and social needs of our patients and their families.


Research is a vital part of the Center for Blood Disorders. Our dedicated team is designed to provide leading clinical and translational research in nonmalignant blood disorders. For over 20 years, Dr. Kutlar has conducted groundbreaking research aimed to improve treatment and care for sickle cell disease.

In the News

Woman becomes first in Augusta area to get bone marrow transplant to cure sickle cell disease

Dec. 25, 2017Augusta Chronicle

Alexis Jones-Heggs, was the first in the Augusta area to receive a bone-marrow transplant to try and cure her of sickle cell disease as part of a national clinical trial that involves the Sickle Cell Center at Augusta University.

Continue Reading

MCG, AU Health participate in first, large NIH-funded study of bone marrow transplant to cure sickle cell disease

Oct. 30, 2017JagWire

The Medical College of Georgia and Augusta University Health have joined the first large national clinical trial to determine if bone marrow transplantation should be part of the standard of care for patients with sickle cell disease.

Continue Reading



Sickle Cell Disease Studies

The Role of Endothelin-1 in Sickle Cell Disease

A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

A Phase 3 Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

A Study to Compare Bone Marrow Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease (BMT CTN 1503) (STRIDE 2)
Principal Investigator: Jeremy Pantin, MD
Contact: Latanya Bowman, RN, BSN 706-721-2171 or Gita Giddens RN, BSN, OCN 706-721-1374

Sickle Cell Disease Implementation Consortium (SCDIC) Registry

Research activities are mostly sponsored by the National Institutes of Health and pharmaceutical companies.